159 related articles for article (PubMed ID: 35210298)
1. Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.
Yang Z; Li F; Huang Y; Yin N; Chu J; Ma Y; Pettigrew RI; Hamilton DJ; Martin DR; Li Z
J Nucl Med; 2022 Nov; 63(11):1708-1714. PubMed ID: 35210298
[TBL] [Abstract][Full Text] [Related]
2. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
[TBL] [Abstract][Full Text] [Related]
3. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
4. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
5. MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids.
Pickles OJ; Wanigasooriya K; Ptasinska A; Patel AJ; Robbins HL; Bryer C; Whalley CM; Tee L; Lal N; Pinna CMA; Elzefzafy N; Taniere P; Beggs AD; Middleton GM
Cancer Res Commun; 2023 Aug; 3(8):1501-1513. PubMed ID: 37565053
[TBL] [Abstract][Full Text] [Related]
6. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
[TBL] [Abstract][Full Text] [Related]
7. IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.
Gibson HM; McKnight BN; Malysa A; Dyson G; Wiesend WN; McCarthy CE; Reyes J; Wei WZ; Viola-Villegas NT
Cancer Res; 2018 Oct; 78(19):5706-5717. PubMed ID: 30115693
[TBL] [Abstract][Full Text] [Related]
8. Site-Specific Immuno-PET Tracer to Image PD-L1.
Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
[TBL] [Abstract][Full Text] [Related]
9. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
11. Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
Nisnboym M; Vincze SR; Xiong Z; Sneiderman CT; Raphael RA; Li B; Jaswal AP; Sever RE; Day KE; LaToche JD; Foley LM; Karimi H; Hitchens TK; Agnihotri S; Hu B; Rajasundaram D; Anderson CJ; Blumenthal DT; Pearce TM; Uttam S; Nedrow JR; Panigrahy A; Pollack IF; Lieberman FS; Drappatz J; Raphael I; Edwards WB; Kohanbash G
Cancer Res Commun; 2023 Jul; 3(7):1173-1188. PubMed ID: 37426447
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
13. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
14. Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors.
Hackett JB; Ramos N; Barr S; Bross M; Viola NT; Gibson HM
Front Oncol; 2023; 13():1285117. PubMed ID: 38130991
[TBL] [Abstract][Full Text] [Related]
15. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
[TBL] [Abstract][Full Text] [Related]
16. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
[No Abstract] [Full Text] [Related]
17. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Maute RL; Gordon SR; Mayer AT; McCracken MN; Natarajan A; Ring NG; Kimura R; Tsai JM; Manglik A; Kruse AC; Gambhir SS; Weissman IL; Ring AM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6506-14. PubMed ID: 26604307
[TBL] [Abstract][Full Text] [Related]
18. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.
Mayer KE; Mall S; Yusufi N; Gosmann D; Steiger K; Russelli L; Bianchi HO; Audehm S; Wagner R; Bräunlein E; Stelzl A; Bassermann F; Weichert W; Weber W; Schwaiger M; D'Alessandria C; Krackhardt AM
Theranostics; 2018; 8(21):6070-6087. PubMed ID: 30613283
[TBL] [Abstract][Full Text] [Related]
19. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
